Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies

Add time:07/11/2019    Source:sciencedirect.com

Through virtual screening, we identified the lead compound MCL1020, which exhibited modest CHK1 inhibitory activity. Then a series of 5-(pyrimidin-2-ylamino)picolinonitrile derivatives as CHK1 inhibitors were discovered by further rational optimization. One promising molecule, (R)-17, whose potency was one of the best, had an IC50 of 0.4 nM with remarkable selectivity (>4300-fold CHK1 vs. CHK2). Compound (R)-17 effectively inhibited the growth of malignant hematopathy cell lines especially Z-138 (IC50: 0.013 μM) and displayed low affinity for hERG (IC50 > 40 μM). Moreover, (R)-17 significantly suppressed the tumor growth in Z-138 cell inoculated xenograft model (20 mg/kg I.V., TGI = 90.29%) as a single agent with body weight unaffected. Taken together, our data demonstrated compound (R)-17 could be a promising drug candidate for the treatment of hematologic malignancies.

We also recommend Trading Suppliers and Manufacturers of (R)-3-(4-broMo-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (cas 1146629-83-5). Pls Click Website Link as below: cas 1146629-83-5 suppliers

Prev:PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells
Next:Tris(4-bromo-1H-pyrazol-1-yl)borato derivatives of first-row transition and group 12 and 14 metals. X-ray crystal structure of [HB(4-Brpz)3]2 Cd. 113Cd solution NMR study of bis[poly(pyrazolyl)borato]cadmium complexes)